Navigation Links
Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report
Date:1/27/2009

Greatest ROI Opportunity for Consumers in Shortest Period of Time

WASHINGTON, Jan. 27 /PRNewswire/ -- As the new administration examines the potential investment in targeted therapies that utilize personalized medicine to improve patient care, a new report released today by the Deloitte Center for Health Solutions found significant opportunities for the adoption of personalized medicine to produce a positive return on investment across key stakeholders in the U.S. health care system. The report, released today at the Personalized Medicine Coalition conference, "Achieving ROI in Personalized Medicine: Barriers, Incentives and Pathways to Successful Commercialization," also found that consumers stand to gain the most significant ROI opportunity within the shortest time period.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090127/NY63078)

"Personalized medicine is not a promise of the future; it is fast emerging as the current state in diagnostics and therapeutics," said Terry Hisey, vice chairman and U.S. industry leader for Deloitte LLP's Life Sciences industry group. "The U.S. health care system will confront an array of challenges to expedite development to make personalized medicine a reality. Our report examines opportunities to overcome these obstacles, from access to capital to stimulate increased R&D to how to justify coverage by health plans often pressured for short-term savings."

Assessing the barriers and incentives for advancing the adoption of personalized medicine, the Deloitte report, "The ROI for Targeted Therapies: A Strategic Perspective," provides an analysis of personalized medicine's economic value proposition. It examines the importance of ROI for multiple stakeholders -- consumers, diagnostic companies, pharmaceutical and biotechnology companies and payors.

Deloitte
'/>"/>

SOURCE Deloitte
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Adoption of Spinal Nonfusion Technologies Doubled in One Year
2. IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
3. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
4. YM Biosciences announces adoption of renewed Shareholders Rights Plan
5. MDV Expands Team Pursuing Advances in Personalized Medicine
6. Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
7. As personalized, genomic medicine takes off, four developing countries show the way for others
8. OSU to Host National Personalized Health Care Conference
9. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
10. MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions
11. Former CMS Administrator: "Blunt Instrument Policies an Increasingly Bad Fit in Era of Personalized Health Care"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Lewisville, TX (PRWEB) September 18, 2014 ... PVC-C, a FM-4910 listed material, to stay competitive ... industries. These high-performance materials ultimately impact product ... company’s President and owner. , Established in 1980 ... held strong as many fabricators have left the ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  MEI Pharma, Inc. ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at BioCentury,s NewsMakers in the ... 8:30 a.m. Eastern time from the Millennium Broadway Hotel & ... live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
(Date:9/18/2014)... Sept. 18, 2014   Sigma-Aldrich Corporation ... has entered into a new gene editing partnership ... Vector Core. Under the partnership, Sigma-Aldrich will provide ... design consultation, and dedicated gene editing bioinformaticians. ... editing-based research at the U-M Medical School. One ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... Fla. -- Engineers at Florida State Universitys National High Magnetic ... that could literally shed new light on nanoscience and semiconductor ... Helix -- is operational in 2010, researchers will have the ... not only down the bore, or center, of the magnet, ...
... N.J., Oct. 31 Amicus Therapeutics,(Nasdaq: ... molecule,orally-active pharmacological chaperones for the treatment of ... the third quarter of 2007.,On a reported ... Accepted,Accounting Principles (GAAP), Amicus announced a net ...
... Calif., Oct. 31 Align,Technology, Inc. (Nasdaq: ... of straightening teeth without wires or brackets, has ... for Silicon Valley, a,ranking of the fastest growing ... region by Deloitte & Touche USA LLP, one ...
Cached Biology Technology:Let there be light: new magnet design continues magnet lab's tradition of innovation 2Amicus Therapeutics Announces Third Quarter 2007 Financial Results 2Amicus Therapeutics Announces Third Quarter 2007 Financial Results 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 4Amicus Therapeutics Announces Third Quarter 2007 Financial Results 5Amicus Therapeutics Announces Third Quarter 2007 Financial Results 6Amicus Therapeutics Announces Third Quarter 2007 Financial Results 7Amicus Therapeutics Announces Third Quarter 2007 Financial Results 8Align Technology, Inc. Ranked 23rd in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies 2Align Technology, Inc. Ranked 23rd in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies 3
(Date:9/19/2014)... a newly discovered hadrosaur with a truly ... Rhinorex condrupus by paleontologists from North Carolina ... what is now Utah approximately 75 million years ... which translates roughly into "King Nose," was a ... hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are usually ...
(Date:9/19/2014)... A new resource unveiled today by researchers from ... College Dublin provides both experienced and aspiring researchers ... build, and operate robots made from soft, flexible ... printing, laser cutters, and other advances in manufacturing ... important field. Using principles drawn from conventional rigid ...
(Date:9/19/2014)... of Oklahoma biology professor will study the unique bioelectric ... could eventually benefit people,s health. The OU researcher ... energy required to produce the signals used to map ... signals at a rate of 500-600 discharges a second ... the electric fish are extreme, but necessary for survival. ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
... Microbial fuel cells, chemical sensors for your iPhone, and ... batteries, safer nuclear power, and new crime scene investigation ... the science of materials, interfaces, and processing. Detailed press ... 60th International Symposium & Exhibition will take place Oct. ...
... The harmful effects of increasingly popular designer cannabis products ... but now a group of researchers is reporting progress ... published in the ACS journal Analytical Chemistry , ... physicians diagnose and treat the thousands of young adults ...
... This news release is available in French . ... Montreal and the Institut universitaire de gratrie de Montral examined ... without mild cognitive impairment (MCI) at the early stages of ... more cortical thinning and subcortical atrophy over time compared with ...
Cached Biology News:AVS science symposium in Long Beach Oct. 27 -- Nov. 2 2
... 8-iso PGE2 is one of several isoprostanes ... is a potent renal vasoconstrictor in the rat. ... with IC50 values of 0.5 and 5 µM, ... the rat at a concentration of 4 mg/kg/min, ...
... The Centra-CL5R multi-purpose centrifuge offers ... a large assortment of rotor options, ... of laboratory applications., Maximum Versatility , ... 21,000 xg) angle rotors or high-volume (4 ...
...
... The Turn & Cast submarine gel systems used gasketed ... the gel in the tank. Turn it back and ... For added convenience, each Turn & Cast tray is ... near the edge of the tray and one in ...
Biology Products: